This study examines the role of cost-effectiveness ratios (ICERs) and thresholds (CETs) in drug reimbursement in Spain, Italy, and France. Findings show CETs are unofficial and inconsistently applied, with reimbursement decisions mainly driven by clinical benefit, budget impact, and negotiation rather than ICERs.
